company background image
ALTS logo

ALT5 Sigma NasdaqCM:ALTS Stock Report

Last Price

US$2.12

Market Cap

US$30.7m

7D

-9.0%

1Y

474.5%

Updated

25 Nov, 2024

Data

Company Financials

ALT5 Sigma Corporation

NasdaqCM:ALTS Stock Report

Market Cap: US$30.7m

ALT5 Sigma Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ALT5 Sigma
Historical stock prices
Current Share PriceUS$2.12
52 Week HighUS$5.26
52 Week LowUS$0.36
Beta2.15
11 Month Change-24.29%
3 Month Change-13.82%
1 Year Change474.53%
33 Year Change-58.91%
5 Year Change-36.24%
Change since IPO-98.85%

Recent News & Updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15
Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Recent updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15
Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

Mar 31
JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14
JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03
Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

JanOne to acquire Soin Therapeutics

Sep 16

Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Aug 17
Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Mar 21
Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

Nov 19
Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

JanOne adds Nicholas Goeders to scientific advisory board

Jun 15

JanOne advances toward initiation of mid-stage peripheral artery disease trial

Jun 08

JanOne under pressure on pricing $6M stock offering

Jan 29

Shareholder Returns

ALTSUS PharmaceuticalsUS Market
7D-9.0%1.6%2.2%
1Y474.5%9.9%31.6%

Return vs Industry: ALTS exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: ALTS exceeded the US Market which returned 31.6% over the past year.

Price Volatility

Is ALTS's price volatile compared to industry and market?
ALTS volatility
ALTS Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: ALTS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ALTS's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19765Peter Tassiopoulosalt5sigma.com

ALT5 Sigma Corporation operates a next generation blockchain platform. It engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. The company’s products include ALT 5 Prime, an electronic over-the-counter trading platform to buy and sell digital assets; and ALT 5 Pay that enables payment processors to accept digital assets as payments, as well as make payment in digital assets.

ALT5 Sigma Corporation Fundamentals Summary

How do ALT5 Sigma's earnings and revenue compare to its market cap?
ALTS fundamental statistics
Market capUS$30.70m
Earnings (TTM)-US$18.65m
Revenue (TTM)US$7.11m

4.2x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALTS income statement (TTM)
RevenueUS$7.11m
Cost of RevenueUS$3.65m
Gross ProfitUS$3.46m
Other ExpensesUS$22.11m
Earnings-US$18.65m

Last Reported Earnings

Sep 28, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.33
Gross Margin48.65%
Net Profit Margin-262.26%
Debt/Equity Ratio46.4%

How did ALTS perform over the long term?

See historical performance and comparison